Madison, CT (August 9, 2023) – DiagMetrics Inc. announced today that it has been awarded Phase 1 funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program in support of its Mask-Based Diagnostic (MBDTM) for rapid detection of COVID-19 for use by individuals with disabilities. The initial award of $938,784.25 has the potential for Phase 2 funding pending successful completion of Phase 1. The RADx Tech award is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB) and will help DiagMetrics continue the development and validation of its novel Mask Based Diagnostic platform as it progresses to product commercialization.
The RADx Tech program was created to accelerate innovation in the development of COVID-19 tests throughout the pandemic by providing funding and access to technical, regulatory, clinical, and commercial experts. Currently, the one aim of the program is to support the development of more accessible over-the-counter (OTC) COVID-19 tests.
The DiagMetrics’ MBD provides a simple way for users with disabilities to perform a COVID-19 test by themselves. The technology uses Exhaled Breath Condensate (EBC) to detect biomarkers of the SARS-CoV-2 virus. “The user simply puts on a mask, presses a button to activate the test, and breathes normally for a few minutes. The proprietary biosensor and electronics with audio instructions will guide the user through the test and announce the results in a few minutes. This solution allows health officials to quickly respond to existing and new pandemics. We are grateful to the NIH and the RADx Tech program for this award, and we believe we can use this technology for several other conditions,” said John Daniels, J.D., co-founder and CEO.
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
About DiagMetrics
DiagMetrics was founded in 2020 to advance mask-based solutions for rapid diagnostics of Covid-19 with the aim to democratize testing. The Company is working on developing tests for multiple other conditions using exhaled breath condensate such as Flu A/Flu B and RSV and has built a rich global IP portfolio. For more information on DiagMetrics, contact us at info@diagmetrics.com.
